HT
INO icon

Headlands Technologies’s Inovio Pharmaceuticals INO Stock Holding History

Headlands Technologies’s Portfolio INO Stock Details INO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-110,068
Closed -$258K – 756
2025
Q3 		$258K Buy
110,068
+109,730
+32,464% +$210K 0.02% 495
2025
Q2 		$688 Buy
+338
New +$648 ﹤0.01% 1135
2024
Q2 		– Sell
-1,360
Closed -$18.9K – 1357
2024
Q1 		$18.9K Buy
+1,360
New +$11.7K ﹤0.01% 921
2023
Q1 		– Sell
-275
Closed -$5K – 623
2022
Q4 		$5K Buy
+275
New +$6.23K ﹤0.01% 387

Other funds holding INO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Headlands Technologies's INO Position: Q4 2025 in Review

Headlands Technologies sold out of Inovio Pharmaceuticals (INO) in Q4 2025, closing a stake of 110,068 shares — an estimated $258K sold.

Headlands Technologies first reported a position in INO in Q4 2022 and held it in 4 quarters. The position peaked at $258K in Q3 2025. 102 funds tracked by Wall St. Rank hold INO as of Q4 2025.

  • Headlands Technologies reported no remaining Inovio Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Headlands Technologies sold 110,068 Inovio Pharmaceuticals shares in Q4 2025, an estimated $258K.
  • Headlands Technologies first reported a position in Inovio Pharmaceuticals in Q4 2022 and held it in 4 quarters.
  • Headlands Technologies's Inovio Pharmaceuticals position peaked at $258K in Q3 2025.
  • 102 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q4 2025.

Based on Headlands Technologies's 13F filing for Q4 2025, filed 13 Feb 2026.